Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
IODINE-123-BETA-CIT AND IODINE-123-FPCIT SPECT MEASUREMENT OF DOPAMINE TRANSPORTERS IN HEALTHY-SUBJECTS AND PARKINSONS PATIENTS
Autore:
SEIBYL JP; MAREK K; SHEFF K; ZOGHBI S; BALDWIN RM; CHARNEY DS; VANDYCK CH; INNIS RB;
Indirizzi:
YALE UNIV,SCH MED,DEPT DIAGNOST RADIOL TE2,NUCL MED SECT,333 CEDAR STNEW HAVEN CT 06510 YALE UNIV,SCH MED,DEPT DIAGNOST IMAGING NEW HAVEN CT 06510 YALE UNIV,SCH MED,DEPT NEUROL & PSYCHIAT NEW HAVEN CT 06510 DEPT VET AFFAIRS MED CTR W HAVEN CT 00000
Titolo Testata:
The Journal of nuclear medicine
fascicolo: 9, volume: 39, anno: 1998,
pagine: 1500 - 1508
SICI:
0161-5505(1998)39:9<1500:IAISMO>2.0.ZU;2-M
Fonte:
ISI
Lingua:
ENG
Soggetto:
I-123 BETA-CIT; NONHUMAN-PRIMATES; HUMAN BRAIN; SEROTONIN TRANSPORTERS; HUMAN PLASMA; IN-VIVO; DISEASE; BINDING; PET; BIODISTRIBUTION;
Keywords:
DOPAMINE; SPECT; 123-BETA-CARBOMETHOXY-3-BETA-(4-IODOPHENYLTROPANE); DOPAMINE TRANSPORTER; PARKINSONS DISEASE; E-123-FP-CARBOMETHOXY-3-BETA-(4-IODOPHENYLTROPANE);
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
31
Recensione:
Indirizzi per estratti:
Citazione:
J.P. Seibyl et al., "IODINE-123-BETA-CIT AND IODINE-123-FPCIT SPECT MEASUREMENT OF DOPAMINE TRANSPORTERS IN HEALTHY-SUBJECTS AND PARKINSONS PATIENTS", The Journal of nuclear medicine, 39(9), 1998, pp. 1500-1508

Abstract

Iodine-123-beta-carbomethoxy-3 beta-(4-iodophenyltropane) (CIT) has been used as a probe of dopamine transporters in Parkinson's disease patients using SPECT. This tracer has a protracted period of striatal uptake enabling imaging 14-24 hr postinjection for stable quantitative measures of dopamine transporters, and it binds with nanomolar affinityto the serotonin transporter. Iodine-123 fluoro-propyl (FP)CIT is an analog of [(123)1]-beta-CIT and has been shown to achieve peak tracer uptake in the brain within hours postinjection and to provide greater selectivity for the dopamine transporter. The purpose of the present study was to compare [I-123]-beta-CIT with [I-123]-FPCIT in a within-subject design. Methods: Six Parkinson's disease patients and five healthy control subjects participated in one [I-123]-beta-CIT and one [I-123]-FPCIT SPECT scan separated by 7-21 days. Controls were imaged at 24hr postinjection 222 MBq (6 mCi) [I-123]-beta-CIT and serially from 1-6 hr postinjection 333 MBq (9 mCi) [I-123]-FPCIT. Two imaging outcomemeasures were evaluated: (9) the ratio of specific striatal activity to nondisplaceable uptake, also designated V-3(''), at each imaging time point; and (b) the rate of striatal washout of radiotracer expressed as a percent reduction per hr for [I-123]-FPCIT. In addition, venousplasma was obtained from the five control subjects after the [I-123]-FPCIT injection for analysis of radio-metabolites. Results: Both [I-123]-FPCIT and [I-123]-beta-CIT demonstrated decreased striatal uptake in Parkinson's disease patients compared with the controls with a mean of V-3('')= 3.5 and 6.7 for [I-123]-beta-CIT (Parkinson's disease and controls, respectively) and a mean of V-3('') = 1.34 and 3.70 for [I-123]-FPCIT (Parkinson's disease and controls, respectively). For [I-123]-beta-CIT, the mean Parkinson's disease values represented 52% of thecontrol uptake, while the mean [I-123]-FPCIT value for Parkinson's disease patients was 37% of the control values. Analysis of [I-123]-FPCIT time-activity curves for specific striatal counts showed washout rates of 8.2%/hr for Parkinson's disease and 4.9%/hr for controls. Conclusion: These data suggest that SPECT imaging with [I-123]-FPCIT visually demonstrates reductions in striatal uptake similar to [I-123]-beta-CIT. Iodine-123-FPCIT washed out from striatal tissue 15-20 times faster than [I-123]-beta-CIT, and estimates of dopamine transporter loss inParkinson's disease patients were higher for [I-123]-FPCIT than for [I-123]-beta-CIT. This was most likely due to the faster rate of striatal washout and establishment of transient equilibrium binding conditions at the dopamine transporter, which the modeling theory suggests produces an overestimation of dopamine transporter density with relatively greater overestimates in healthy control subjects by [I-123]-FPCIT.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 18/01/20 alle ore 21:29:20